GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

Paris, France, September 19, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced its stock has been included, as of September 18, 2017, in the CAC^® Small, CAC^® Mid and Small and CAC^® All-Tradable indexes following their annual review by the Euronext Scientific Board on Indices.

Please find the full PDF press release attached.

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: Gensight